Korean Companies Step Up Development Of Enbrel Biosimilars As Amgen Ramps Up Its Pipeline
This article was originally published in PharmAsia News
Executive Summary
After halting trials of its Rituxan biosimilar last year, Samsung Bioepis is focusing on its Enbrel biosimilar and has begun Phase I trials. Other Korean pharma are developing biosimilars of Enbrel, with Hanwha expecting approval in Korea this year.